AXSOME THERAPEUTICS, INC.: basic weighted-average shares

What this measure means

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Exact concept: us-gaap:WeightedAverageNumberOfSharesOutstandingBasic. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2020-01-01 to 2025-12-31. The SEC response was captured on 2026-09-19.

Reading these values

This selected numerical history matches Diluted weighted-average shares for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.

Context from the filing

For Axsome in 2023–2025, the EPS note presents the same basic and diluted loss denominator and separately lists excluded anti-dilutive securities for all three years. The general accounting-policy paragraph explicitly names only 2025 and 2024; the three-year exclusion table supplies the 2023 context. The 2025 table includes performance stock units, while that row is zero for 2024 and 2023. Options, restricted stock units, warrants and ESPP shares are also listed. Full scale-zero share counts and EPS are retained under the share/per-share exception to the thousands heading. Read the source filing.

Selected filing history

Related financial histories

• AXSOME THERAPEUTICS, INC.: total assets
• AXSOME THERAPEUTICS, INC.: total liabilities
• AXSOME THERAPEUTICS, INC.: stockholders equity
• AXSOME THERAPEUTICS, INC.: cash and cash equivalents
• AXSOME THERAPEUTICS, INC.: net income or loss
• AXSOME THERAPEUTICS, INC.: operating cash flow
• AXSOME THERAPEUTICS, INC.: capital expenditure payments
• AXSOME THERAPEUTICS, INC.: contract revenue excluding tax
• AXSOME THERAPEUTICS, INC.: financing cash flow
• AXSOME THERAPEUTICS, INC.: investing cash flow
• AXSOME THERAPEUTICS, INC.: retained earnings or deficit
• AXSOME THERAPEUTICS, INC.: diluted weighted-average shares
• AXSOME THERAPEUTICS, INC.: basic earnings per share
• AXSOME THERAPEUTICS, INC.: diluted earnings per share
• AXSOME THERAPEUTICS, INC.: income tax expense or benefit
• AXSOME THERAPEUTICS, INC.: net property, plant and equipment
• AXSOME THERAPEUTICS, INC.: share-based compensation expense
• AXSOME THERAPEUTICS, INC.: operating income or loss
• AXSOME THERAPEUTICS, INC.: current assets
• AXSOME THERAPEUTICS, INC.: interest expense
• AXSOME THERAPEUTICS, INC.: current liabilities
• AXSOME THERAPEUTICS, INC.: current accounts payable
• AXSOME THERAPEUTICS, INC.: goodwill carrying amount
• AXSOME THERAPEUTICS, INC.: net finite-lived intangible assets
• AXSOME THERAPEUTICS, INC.: net current accounts receivable
• AXSOME THERAPEUTICS, INC.: operating expenses
• AXSOME THERAPEUTICS, INC.: net inventory
• AXSOME THERAPEUTICS, INC.: selling, general and administrative expense
• AXSOME THERAPEUTICS, INC.: research and development expense

Inspect the source

Entity

AXSOME THERAPEUTICS, INC. / CIK 0001579428

Captured

2026-09-19T11:19:11.812Z

SEC response SHA-256

bb534249e79901f14ef56a7cde4d7cfc00d4e7cc31cc09f237146d8a497ea5fc

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001579428.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))